Pembrolizumab/177Lu-PSMA-617 May Be a New Treatment for Patients with mCRPC
November 1st 2023Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.